Quarterly ResultMay 7, 2026, 07:17 AM
Aclaris Q1 Net Loss $19.8M; ATI-052 Phase 1a Exceeds Target
AI Summary
Aclaris Therapeutics reported a net loss of $19.8 million for Q1 2026, compared to $15.1 million in Q1 2025, with total revenue increasing to $2.0 million. The company announced positive full top-line results from its Phase 1a trial of ATI-052, exceeding its target profile and showing potential for extended dosing. Aclaris also confirmed a strong cash position of $190.8 million, expected to fund operations through 2028, and provided updates on other pipeline candidates including planned Phase 2b trials for ATI-052 and ATI-2138.
Key Highlights
- Q1 2026 net loss was $19.8 million, compared to $15.1 million in Q1 2025.
- Total revenue for Q1 2026 increased to $2.0 million from $1.5 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $190.8 million as of March 31, 2026.
- Company expects cash runway to fund operations through the end of 2028.
- ATI-052 Phase 1a trial showed positive full top-line results, exceeding target profile.
- ATI-052 Phase 1b POC trial results for asthma and AD expected in H2 2026.
- ATI-2138 Phase 2b basket study for lichen planus to initiate in H2 2026.
- Bosakitug Phase 2 trial top-line results for AD expected in Q4 2026.